ag-1296 has been researched along with bromodeoxyuridine in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Enjoji, M; Iwamoto, H; Nakamuta, M; Nawata, H; Sugimoto, R; Tada, S | 1 |
1 other study(ies) available for ag-1296 and bromodeoxyuridine
Article | Year |
---|---|
Platelet-derived growth factor receptor tyrosine kinase inhibitor AG1295 attenuates rat hepatic stellate cell growth.
Topics: Animals; Becaplermin; Blotting, Western; Bromodeoxyuridine; Cells, Cultured; DNA; Dose-Response Relationship, Drug; Isoenzymes; Liver; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phospholipase C gamma; Phosphorylation; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-sis; Proto-Oncogene Proteins p21(ras); Rats; Rats, Wistar; Receptor, Platelet-Derived Growth Factor beta; Type C Phospholipases; Tyrphostins | 2000 |